Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSB-OR-2020
- Development stage
- Unknown
- Lead developer
- University of Bonn
01
Overview
PSB-OR-2020: sourced facts only. name: "The allosteric P2X4 receptor antagonists BX430 and 5-BDBD displayed notable species differences, while the indole derivative PSB-OR-2020 blocked all investigated mammalian species with high potency (0.696-6.32 nM), exhibiting only minor species differences." [PMID:40370986]; target: "The allosteric P2X4 receptor antagonists BX430 and 5-BDBD displayed notable species differences, while the indole derivative PSB-OR-2020 blocked all investigated mammalian species with high potency (0.696-6.32 nM), exhibiting only minor species differences." [PMID:40370986]; developer: "PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany." [PMID:40370986]
02
Targets
P2RX4 (P2X Purinoceptor 4)
Beyond the preview
Go deeper on PSB-OR-2020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSB-OR-2020.